Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients

Conditions

Nasopharyngeal Carcinoma

Keywords

plasma EBV DNA, nasopharyngeal carcinoma, longitudinal surveillance

Brief summary

Endemic nasopharyngeal carcinoma (NPC) is invariably associated with Epstein-barr virus (EBV) infection. Plasma EBV DAN detected by polymerase chain reaction (PCR)-based assays can provide important informations of disease screening, disease relapse, and risks classification. In this study, the investigators will explore the impact of serial plasma EBV DNA during chemotherapy and radiotherapy on initial tumor response and long-term survival in patients with non-metastatic nasopharyngeal carcinoma

Lv J, Zheng DX, Liang JH, Zhang N, Ye ZL, Xu XD, Chua MLK, Zhang LL, Du ZM, Zhang ZC, Li WF, Tang LL, Chen L, Mao YP, Guo R, Chen YP, Lin L, Zhang Y, Liu X, Xu C, Li ZX, Xu LX, Yang PY, Chen K, Bin D, Gao TS, Yan JY, Chen LS, Huang SH, Zhao HY, Hong SB, Jie YS, Huang HL, Tang XH, Yun JP, Liu LZ, Tian L, Li HJ, Li JB, Zhou GQ, Ma J, Sun Y.

2026-03-11

10.1038/s41586-026-10244-w

Establishment and validation of a dynamic prognostic model using serial circulating tumor DNA (ctDNA) for endemic EBV-related nasopharyngeal carcinoma (NPC): A secondary analysis of EP-SEASON.

Zi-Cheng Zhen, Wenbing Lv, Fangfang Yang, Ling-Xin Xu, Ting-Qiu Quan et al. (10 authors)

Journal of Clinical Oncology2025-05-28

10.1200/jco.2025.43.16_suppl.6049

Longitudinal tracing of on-treatment plasma Epstein-Barr virus DNA as a biomarker for real-time dynamic risk monitoring in patients with nasopharyngeal carcinoma: The EP-SEASON study.

Ling-Xin Xu, Zhixuan Li, Li Lin, Chen‐Fei Wu, Guan-Qun Zhou et al. (8 authors)

Journal of Clinical Oncology2024-08-10

10.1200/jco.2024.42.23_suppl.136

Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study

Jia‐Wei Lv, Ling-Xin Xu, Zhi‐Xuan Li, Li Lin, Chen‐Fei Wu et al. (22 authors)

Cancer Cell2024-07-2548 citations

10.1016/j.ccell.2024.07.001

Interventions

DIAGNOSTIC_TESTPlasma EBV DNA

Parameters analyzed will include (1) the changing pattern of plasma EBV DNA concentrations during chemotherapy and radiotherapy (2) half-life values (t1/2) of plasma EBV DNA clearance rate

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

1. Patients with newly histologically confirmed non-keratinizing carcinoma (according to WHO histological type) 2. No evidence of distant metastasis (M0) 3. Receive standard radical treatment 4. Not exhibiting overt psychopathology, and willing to participate and written informed consent was obtained

Exclusion criteria

1. WHO type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma. 2. Treatment with palliative intent 3. Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) 4. Severe intercurrent disease

Design outcomes

Primary

Measure	Time frame	Description
Progression-free survival	3 years	Progression-free survival is calculated from the date of diagnosis of NPC to the date of progression of NPC or the date of death from any cause, whichever comes earlier.

Secondary

Measure	Time frame	Description
overall survival	3 years	Overall survival is calculated from the date of diagnosis of NPC to the date of death from any cause
Distant metastasis-free survival	3 years	Distant metastasis-free survival is calculated from the date of diagnosis of NPC to the date of distant metastasis or date of death from any cause, whichever comes earlier.
locoregional failure-free survival	3 years	Local or regional failure-free survival is calculated from the date of diagnosis of NPC to the date of regional nodal failure or date of death from any cause, whichever comes earlier.
EBV DNA clearance rate	during the first month	The half-life value (t1/2) of plasma EBV DNA clearance was calculated using the equation of \[t1/2 = 0.693/k\].

Countries

China

Outcome results

None listed